Positive grass allergy tablet data from Merck as advisory meeting looms
This article was originally published in Scrip
Merck has reported positive results for its Timothy grass sublingual immunotherapy tablet (MK-7243), licensed from ALK, including pediatric data. The BLA for the product was filed in January this year, and accepted for review in March (scripintelligence.com, 28 March 2013). Merck expects the US FDA's review for to be completed in the first half of 2014, but has not released the PDUFA date.